When Gleevec was invented, or when it came out, that was a game-changer for patients with GIST, because they previously had ...

Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing at a CAGR of 6.4% during 2025–2035.

Olverembatinib shows promise in treating SDH-deficient GISTs, a rare tumor type with limited treatment options and high relapse risk. The phase 1b study demonstrated a 23.1% objective response rate ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...

Ascentage Pharma Group International Unsponsored ADR ( ($AAPG) ) has issued an update. On November 24, 2025, Ascentage Pharma announced the ...

In Naples, today December 5th and tomorrow, the important scientific meeting "Hot Topics on Sarcomas: Precision, Proximity, ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety ...

-- Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin -- Sapablursen was generally safe and well ...

Learn more about whether Nurix Therapeutics, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.